Cargando…

Characterization and burden of severe eosinophilic asthma in New Zealand: Results from the HealthStat Database

BACKGROUND: This retrospective cohort study aimed to characterize epidemiology, medication use and healthcare resource utilization (HCRU) of patients diagnosed with severe eosinophilic asthma (SEA) compared to other patients with asthma in New Zealand. METHODS: Adult patients with asthma with no con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shantakumar, Sumitra, Ho, Yu-Fan, Beale, Janine, Gribben, Barry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460659/ https://www.ncbi.nlm.nih.gov/pubmed/32983453 http://dx.doi.org/10.4081/mrm.2020.662

Ejemplares similares

Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database
por: Milea, Dominique, et al.
Publicado: (2021)

A survey of management practices in coexistent allergic rhinitis and asthma (Asia-pacific Survey of Physicians on Asthma and allergic Rhinitis): results from Thailand
por: Bunupuradah, Torsak, et al.
Publicado: (2019)

Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study
por: Shantakumar, Sumitra, et al.
Publicado: (2018)

Severe Eosinophilic Asthma
por: Bakakos, Agamemnon, et al.
Publicado: (2019)

Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR): physician beliefs and practices about diagnosis, assessment, and treatment of coexistent disease
por: Aggarwal, Bhumika, et al.
Publicado: (2018)

Asia Pacific survey of physicians on asthma and allergic rhinitis (ASPAIR): data from China
por: Hinds, David, et al.
Publicado: (2019)

Burden of asthma with elevated blood eosinophil levels
por: Casciano, Julian, et al.
Publicado: (2016)

Eosinophilic bioactivities in severe asthma
por: Carr, Tara F., et al.
Publicado: (2016)

Global Burden of Asthma, and Its Impact on Specific Subgroups: Nasal Polyps, Allergic Rhinitis, Severe Asthma, Eosinophilic Asthma
por: Rabe, Adrian Paul J, et al.
Publicado: (2023)

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
por: Van Hulst, Glenn, et al.
Publicado: (2021)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma
por: Choi, Youngwoo, et al.
Publicado: (2018)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Severe eosinophilic asthma in Chinese C‐BIOPRED asthma cohort
por: Zhang, Qingling, et al.
Publicado: (2022)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

COVID-19, Eosinophils, and Biologicals for Severe Asthma
por: Lombardi, Carlo, et al.
Publicado: (2022)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
por: Martínez-Rivera, Carlos, et al.
Publicado: (2021)

Role of biologics in severe eosinophilic asthma – focus on reslizumab
por: Pelaia, Girolamo, et al.
Publicado: (2016)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Eosinophils Target Therapy for Severe Asthma: Critical Points
por: Brussino, L., et al.
Publicado: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma
por: Tepetam, Fatma Merve, et al.
Publicado: (2023)

Reforming primary health care: is New Zealand's primary health care strategy achieving its early goals?
por: Cumming, Jacqueline, et al.
Publicado: (2008)

Characterization and Factors Associated with Poor Asthma Control in Adults with Severe Eosinophilic Asthma
por: Padró-Casas, Clara, et al.
Publicado: (2023)

PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study
por: Abi Saleh, Wajdi, et al.
Publicado: (2023)

Eosinophils and childhood asthma
por: Choi, Bong Seok
Publicado: (2021)

Development of a real-world database for asthma and COPD: The SingHealth-Duke-NUS-GSK COPD and Asthma Real-World Evidence (SDG-CARE) collaboration
por: Lam, Sean Shao Wei, et al.
Publicado: (2023)

Eosinophilic esophagitis incidence in New Zealand: high but not increasing
por: Weerasekera, Kavindu, et al.
Publicado: (2019)

Value of peripheral blood eosinophil markers to predict severity of asthma
por: Casciano, Julian, et al.
Publicado: (2016)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
por: Vatrella, Alessandro, et al.
Publicado: (2022)

Bronchiectasis in severe asthma is associated with eosinophilic airway inflammation and activation
por: Frøssing, Laurits, et al.
Publicado: (2022)

Clinical burden of illness among patients with severe eosinophilic COPD
por: Müllerová, Hana, et al.
Publicado: (2019)

Anti‐interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis
por: Tomyo, Fuminori, et al.
Publicado: (2018)

Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pkujhfg3u1391gp3s3p07bvr7m